A young child of anti-NMDA receptor encephalitis presenting with epilepsia partialis continua: the first pediatric case in Korea.
10.3345/kjp.2016.59.11.S133
- Author:
Eun Hee KIM
1
;
Yeo Jin KIM
;
Tae Sung KO
;
Mi Sun YUM
;
Jun Hwa LEE
Author Information
1. Department of Pediatrics, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Anti-N-methyl-D-aspartate receptor encephalitis;
Epilepsia partialis continua;
Child
- MeSH:
Anti-N-Methyl-D-Aspartate Receptor Encephalitis*;
Antibodies;
Anticonvulsants;
Antihypertensive Agents;
Cerebrospinal Fluid;
Child*;
Child, Preschool;
Cognition;
Consciousness;
D-Aspartic Acid;
Diagnosis;
Dyskinesias;
Encephalitis;
Epilepsia Partialis Continua*;
Female;
Fever;
Humans;
Immunoglobulins;
Immunotherapy;
Korea*;
Methylprednisolone;
Rituximab;
Seizures;
Virus Diseases
- From:Korean Journal of Pediatrics
2016;59(Suppl 1):S133-S138
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anti-N-methyl D-aspartate receptor (anti-NMDAR) encephalitis, recently recognized as a form of paraneoplastic encephalitis, is characterized by a prodromal phase of unspecific illness with fever that resembles a viral disease. The prodromal phase is followed by seizures, disturbed consciousness, psychiatric features, prominent abnormal movements, and autonomic imbalance. Here, we report a case of anti-NMDAR encephalitis with initial symptoms of epilepsia partialis continua in the absence of tumor. Briefly, a 3-year-old girl was admitted to the hospital due to right-sided, complex partial seizures without preceding febrile illness. The seizures evolved into epilepsia partialis continua and were accompanied by epileptiform discharges from the left frontal area. Three weeks after admission, the patient's seizures were reduced with antiepileptic drugs; however, she developed sleep disturbances, cognitive decline, noticeable oro-lingual-facial dyskinesia, and choreoathetoid movements. Anti-NMDAR encephalitis was confirmed by positive detection of NMDAR antibodies in the patient's serum and cerebrospinal fluid, and her condition slowly improved with immunoglobulin, methylprednisolone, and rituximab. At present, the patient is no longer taking multiple antiepileptic or antihypertensive drugs. Moreover, the patient showed gradual improvement of motor and cognitive function. This case serves as an example that a diagnosis of anti-NMDAR encephalitis should be considered when children with uncontrolled seizures develop dyskinesias without evidence of malignant tumor. In these cases, aggressive immunotherapies are needed to improve the outcome of anti-NMDAR encephalitis.
